top of page

Home
About
Services
Partners & Network
Resources
- Events
Schedule a call
More

Use tab to navigate through the menu items.

Knowledge Hub: Articles

Scroll to Events

All Posts
Business Development
Biosimilars
Generics
Oncology
Covid-19

Search

Why biosimilars are an opportunity, but could also be a trap.

Why biosimilars are an opportunity, but could also be a trap.

Why biosimilars are an opportunity, but could also be a trap.

The Second Wave of Biosimilars. How to find the best ones?

The Second Wave of Biosimilars. How to find the best ones?

The Second Wave of Biosimilars. How to find the best ones?

13 recommendations to succeed when selecting 2nd wave biosimilars.

13 recommendations to succeed when selecting 2nd wave biosimilars.

13 recommendations to succeed when selecting 2nd wave biosimilars.

Tenders and long term sustainability of biosimilars in Europe

Tenders and long term sustainability of biosimilars in Europe

Tenders and long term sustainability of biosimilars in Europe

Biosimilars to increase adoption of biologics in Emerging Markets. Past Evidence for the Future.

Biosimilars to increase adoption of biologics in Emerging Markets. Past Evidence for the Future.

Biosimilars to increase adoption of biologics in Emerging Markets. Past Evidence for the Future.

At least 255 pharmaceuticals playing biosimilars. Rise of the "Pharmerging" middle class.

At least 255 pharmaceuticals playing biosimilars. Rise of the "Pharmerging" middle class.

At least 255 pharmaceuticals playing biosimilars. Rise of the "Pharmerging" middle class.

Is it true that biosimilars will increase the use of the molecule? Not always...

Is it true that biosimilars will increase the use of the molecule? Not always...

Is it true that biosimilars will increase the use of the molecule? Not always...

Commercial strategies for biosimilars: Any sense to register several brands?

Commercial strategies for biosimilars: Any sense to register several brands?

Commercial strategies for biosimilars: Any sense to register several brands?

Anti TNF biosimilars infliximab and etanercept conquer 63% and 44% of the Top 5 EU in under 3 years.

Anti TNF biosimilars infliximab and etanercept conquer 63% and 44% of the Top 5 EU in under 3 years.

Anti TNF biosimilars infliximab and etanercept conquer 63% and 44% of the Top 5 EU in under 3 years.

Biosimilars following same pattern as generics? Neupogen keeps just 6% of EU market after 10 years.

Biosimilars following same pattern as generics? Neupogen keeps just 6% of EU market after 10 years.

Biosimilars following same pattern as generics? Neupogen keeps just 6% of EU market after 10 years.

Biosimilars of Rituximab grab 50% market share in top EU markets after less than 2 years.

Biosimilars of Rituximab grab 50% market share in top EU markets after less than 2 years.

Biosimilars of Rituximab grab 50% market share in top EU markets after less than 2 years.

Notes on the German generics and biosimilars market 2016-2018.

Notes on the German generics and biosimilars market 2016-2018.

Notes on the German generics and biosimilars market 2016-2018.

Events

Don't Miss Out on Our Events

Subscribe to our newsletter and stay in the loop

Add your email here

Thanks for submitting!

128 Moo 3, Tambol Padad, Amphur Muang,

50100 Chiang Mai, Thailand

Senora Sergia, 2A, Piso 1A

28250 Torrelodones, Spain

Jose Ignacio Diaz
Senior advisor

Copyright © 2023 Emergpharma Group. All rights reserved.

bottom of page